DC-HIL in cancer

DC-HIL 在癌症中的应用

• 批准号: 10265335
• 负责人: PONCIANO D CRUZ
• 金额: --
• 依托单位: VA NORTH TEXAS HEALTH CARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10265335
• 关键词: Address; Adoptive Transfer; Animals; Antigen-Presenting Cells; Antitumor Response; Binding; Biological Assay; Biological Response Modifiers; Blood; CD8-Positive T-Lymphocytes; CTLA4 gene; Cancer Model; Cancer Patient; Cell physiology; Cells; Colon; Colon Carcinoma; Enhancers; Gene Deletion; Growth; Heparitin Sulfate; Immune Targeting; Immune checkpoint inhibitor; Immunologics; Inflammatory; Kinetics; Lead; Ligands; MC38; Malignant Neoplasms; Measures; Mediator of activation protein; Metastatic Melanoma; Metastatic Neoplasm to the Lung; Minority; Modality; Modeling; Monoclonal Antibodies; Morbidity - disease rate; Mus; Myeloid-derived suppressor cells; Neoplasm Metastasis; Outcome; PD-1/PD-L1; PDL1 pathway; Pathway interactions; Patients; Polysaccharides; Proliferating; Prostate; Regulation; Resistance; SILV gene; Signal Transduction; Solid Neoplasm; Suppressor-Effector T-Lymphocytes; T-Cell Activation; T-Lymphocyte; Time; Treatment Efficacy; Tumor Immunity; anti-PD-1; anti-PD-L1 therapy; anti-cancer; anticancer treatment; cancer immunotherapy; cancer therapy; cell transformation; immune checkpoint; immune checkpoint blockers; immunogenicity; improved; inhibitor/antagonist; lung Carcinoma; melanoma; monoclonal antibody LL2; mortality; mouse model; novel; optimal treatments; programmed cell death ligand 1; programmed cell death protein 1; promoter; receptor; syndecan-4; tumor

Melanoma and other cancers continue to cause significant morbidity and mortality. Having discovered an immune regulator (DC-HIL) whose function can be manipulated to treat cancers, we will: (1) determine whether DC-HIL accounts for resistance to current cancer immunotherapy; (2) characterize the combination of mAb against immune targets that produces optimal treatment benefits; and (3) elucidate how blocking the DC-HIL ligand (syndecan-4) on T cells leads to better outcomes for cancer treatments. Our results will improve current management of metastatic melanoma and other cancers.

黑色素瘤和其他癌症继续造成严重的发病率和死亡率。